dostarlimab-gxly
FDA Approves First Engineered T Cell Therapy for Solid Tumors, Expands GSK’s Jemperli
FDA approval, engineered T cell therapy, solid tumors, GSK’s Jemperli, dostarlimab-gxly, afamitresgene autoleucel, Tecelra, endometrial cancer, synovial sarcoma
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival